Allarta Life Sciences Inc.

Regenerative medicine and cell therapies for endocrine disorders are potentially curative treatments for diabetes, rare lysosomal disorders, and hemophilia. These current therapies face a roadblock of immune rejection unless patients are placed on invasive and difficult immune-suppressive drugs. Allarta Life Science is developing platform technology that would enable allogenic implants of, for example, insulin-producing Beta cells, without the need for systemic immune suppression. This immune-evasive technology will be critical in the global commercialization and accessibility of regenerative medicine treating endocrine disorders. The current market for regenerative medicine is estimated to be $20B annually with T1D and T2D comprising $700B annually.

Contact: Harald Stover, CEO & Founder,